QRG Capital Management Inc. Sells 77,977 Shares of Astrazeneca Plc $AZN

by · The Markets Daily

QRG Capital Management Inc. reduced its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 44.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 97,737 shares of the company’s stock after selling 77,977 shares during the quarter. QRG Capital Management Inc.’s holdings in Astrazeneca were worth $19,189,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. IHT Wealth Management LLC lifted its position in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after purchasing an additional 54 shares during the period. Visionary Wealth Advisors grew its stake in Astrazeneca by 1.5% during the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares in the last quarter. Vista Investment Management increased its holdings in Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after buying an additional 60 shares during the period. Kestra Investment Management LLC increased its holdings in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after buying an additional 63 shares during the period. Finally, Luken Investment Analytics LLC raised its position in shares of Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after buying an additional 64 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on AZN shares. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Finally, Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and an average target price of $205.33.

View Our Latest Stock Analysis on AZN

Astrazeneca Trading Down 0.1%

AZN opened at $194.96 on Friday. The company has a market cap of $302.36 billion, a P/E ratio of 29.27, a PEG ratio of 1.58 and a beta of 0.24. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company’s 50 day moving average is $183.96 and its 200-day moving average is $187.95. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Equities research analysts predict that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

About Astrazeneca

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

See Also